ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO659

Combination of Different Urinary Omics Traits Improves the Prediction of Postnatal Renal Outcome in Fetuses with Posterior Urethral Valves (PUV)

Session Information

  • Pediatric Nephrology
    November 02, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Developmental Biology and Inherited Kidney Diseases

  • 403 Pediatric Nephrology


  • Buffin-Meyer, Benedicte, Inserm U1048, Toulouse, France
  • Klein, Julie, Inserm U1048, Toulouse, France
  • Muller, Francoise, Inserm U1048, Toulouse, France
  • Breuil, Benjamin, Inserm U1048, Toulouse, France
  • Moulos, Panagiotis, Inserm U1048, Toulouse, France
  • Nadia, Lounis, Inserm U1048, Toulouse, France
  • Bascands, Jean-loup, Inserm U1048, Toulouse, France
  • Decramer, Stéphane, Inserm U1048, Toulouse, France
  • Schanstra, Joost, Inserm U1048, Toulouse, France

Urinary omics-based strategies are promising tools in medicine as they have already led to the design of multimarker models for the assessment of complex diseases. Nevertheless, advances still need to be made since most models using single omics traits are unable to reach a 100% accuracy and display a so-called “gray zone” defined by the uncertainty of the prediction. Here we verified the hypothesis whether a combination of urinary fetal peptides and metabolites provides an improved prediction of postnatal renal function in fetuses with PUV compared to the individual omics traits.


Using capillary electrophoresis coupled to mass spectrometry, we explored the urinary metabolome from 13 PUV fetuses with early ESRD and 12 PUV fetuses without postnatal ESRD at 2 years.


This allowed the identification of 24 differentially abundant fetal urinary metabolites which were modelled into a svm classifier, alone or in combination with 12 peptides predictive of disease progression (Klein et al, PMID:23946195). The predictive capacities of models composed of metabolites (24m model), peptides (12p model) or association of both (24m_12p model) were compared in a separate independent validation cohort of 35 fetuses with PUV. The gray zone was generated as the range of svm scores for which the negative likelihood ratio (LR) was >0.05 and the positive LR was <20. Sensitivity, specificity (excluding patients in gray zone) as well as area under the ROC curve (AUC) and net reclassification improvements (NRI) of PUV patients were evaluated (Table 1).


While the individual metabolome- and peptidome-based models already display high accuracy for identification of the disease classes, the discriminative power can be significantly improved by combination of omics traits. This supports the general concept that multi-omics approaches can improve the clinical assessment of disease.

Table 1
Sensitivity (%)50.0 [25 - 74]81.3 [62 - 100]87.5 [71 - 100]*
Specificity (%)68.4 [47 - 89]78.9 [61 - 97]84.2 [68 - 100]
AUC0.90 [0.79-1]0.97 [0.91-1]0.99 [0.96-1]
NRI versus 24m (%)  36.5 [4-69]§
NRI versus 12p (%)  11.5 [0-39]

*p<0.05 vs 24m, §p<0.05 vs 0.


  • Private Foundation Support